- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02312804
Ph Ib/BGJ398/Cervix and Other Solid Tumors
February 13, 2015 updated by: Steven Weitman, The University of Texas Health Science Center at San Antonio
A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors
This study will be conducted using 3+3 design and includes, a dose escalation part to define the MTDfRP2D for the combination of BGJ398 and carboplatin/paclitaxel, and a dose expansion part to treat another 12 patients (only cervix cancer) to further evaluate safety of this combination.
Safety, tolerability and MTD will be determined in the dose escalation part of the study.
The dose expansion will additionally investigate preliminary anti-tumor efficacy in cervical cancer.
The dosing cycle is 21 days.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects age >18 years at the time of informed consent
- Histologically/cytologically confirmed locally advanced or metastatic solid tumors for which no curable therapy exists. In dose expansion part of this study, only patients with stage IV or recurrent/persistent cervical cancer will be enrolled. Confirmation of FGF/FGFR aberration is not required.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate marrow function as defined below:
absolute neutrophil count ≥ 1.5 x 10 9/L platelets ≥ 100,000 x 10 9/L hemoglobin ≥ 9.0 g/dL Adequate liver function as evidenced by bilirubin <1.5 times the upper limit of normal (ULN); alanine aminotransferase (AL T) and aspartate aminotransferase (AST) <3 times the ULN
- Evidence of measurable or evaluable disease, as determined by RECIST v 1.1
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least 12 consecutive months (Le., has had menses at any time in the preceding 12 consecutive months). Oral contraceptives (OC), injected or implanted hormonal methods are not allowed as the sole method of contraception because BGJ398 has not been characterized with respect to its potential to interfere with PK and/or the effectiveness of OCs.
- It is preferred that archival tumor sample is available for molecular testing, if not available, a newly obtained tumor biopsy may be submitted instead (not mandatory)
Exclusion Criteria:
- For patients enrolled in dose escalation, any number of prior treatments allowed. For patients enrolled in dose expansion, no prior chemotherapy is allowed (previous single agent cisplatin concurrent with radiotherapy is accepted).
- No prior therapy with paclitaxel, BGJ398 or other FGFR targeting agents.
- Preexisting> grade 2 peripheral neuropathy
- Patients with brain metastases are allowed provided that they are clinically stable for a period of 30 days prior to study entry and there is not a requirement for steroids or anti epileptics.
- History of pancreatitis in last 6 months prior to enrollment.
- History and/or current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis, or patients with other phosphate regulating abnormalities. Because hyperphosphatemia is a frequent occurrence with BGJ398 treatment, pretreatment and concurrent treatment with phosphate regulating agents is allowed.
- Current evidence of corneal or retinal disorder/ keratopathy such as bullous/ band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivits, etc
- Since BGJ398 is a likely inhibitor of CYP3A4, patients who are currently receiving treatment with agents that are known sting inducers or inhibitors CYP3A4 are not allowed
- Treatment with any of the following anti-cancer therapies prior to the first dose of the of BGJ398 within the stated timeframes: intravenous chemotherapy within a period of 4 weeks ( 6 weeks for nitrosourea, mitomycin-C), biological therapy (e,g. antibodies) within a period of time that is ~ 5 t1/2 or less than 4 weeks, whichever is shorter, prior to starting study drug, any other investigational agents within a period of time that is < 5 tl/2 or 4 weeks (whichever is shortest) prior to starting study drug, wide field radiotherapy < 4 weeks or limited field radiation for palliation < 2 weeks prior to starting study drug.
- Use of medications that increase serum levels of phosphorus and/or calcium.
- History of cardiac disease (Congestive heart failure NYHA grade> 2, LVEF < 50% as determined by MUGA scan or ECHO, history of clinically significant ventricular arrhythmias, unstable angina pectoriS or acute myocardial infarction <6 months prior to starting study drug, QTcF > 450 msec)
- Pregnant or nursing (lactating) women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation
To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
|
BGJ398 will be administered orally once daily on each day of the 21 day cycle.
Other Names:
Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
Other Names:
Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
Other Names:
|
Experimental: Expansion Cervical Cancer
To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
|
BGJ398 will be administered orally once daily on each day of the 21 day cycle.
Other Names:
Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
Other Names:
Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the maximum tolerated dose (MTD) based on toxicity analysis.
Time Frame: approximately 12 months
|
Toxicity will be monitored according to NCI Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0.
|
approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time vs. concentration profile of BGJ398
Time Frame: At Cycle 1 Day 1 and Cycle 2 Day 1
|
Plasma concentration versus time profiles.
Plasma PK parameters will be used to characterize the PK profiles of BGJ398 when combined with certain chemotherapies.
|
At Cycle 1 Day 1 and Cycle 2 Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Steven Weitman, MD, Clinical Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
October 1, 2014
First Submitted That Met QC Criteria
December 5, 2014
First Posted (Estimate)
December 9, 2014
Study Record Updates
Last Update Posted (Estimate)
February 16, 2015
Last Update Submitted That Met QC Criteria
February 13, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Uterine Cervical Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Infigratinib
Other Study ID Numbers
- CTMS 14-2006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
AmgenCompletedSolid Tumors | Oncology | Tumors
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedCancer | Advanced Solid Tumors | TumorsUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
Clinical Trials on BGJ398
-
LianBio LLCRecruitingGastric Cancer | Solid Tumor | Gastroesophageal Junction AdenocarcinomaChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBladder Cancer | Non-Muscle-Invasive Urothelial CarcinomaUnited States
-
Novartis PharmaceuticalsTerminatedSolid Tumor | Hematologic MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors | Metastatic Solid TumorsFrance, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedRecurrent Glioblastoma or Other Glioma SubtypesSpain, Belgium, United States, Switzerland, Australia, Netherlands
-
QED Therapeutics, Inc.Helsinn Healthcare SATerminatedFGFR2 Gene Mutation | Advanced CholangiocarcinomaUnited States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
-
Helsinn Healthcare SALabcorp Drug Development IncWithdrawnAdvanced Solid Tumor | CNS Tumor | Recurrent WHO Grade II GliomaUnited States, Canada, Germany
-
National Institute of Dental and Craniofacial Research...TerminatedOncogenic Osteomalacia | Tumor-Induced OsteomalaciaUnited States
-
University of ChicagoNovartisTerminatedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...United States